How effective is donanemab for patients with higher tau protein levels?

Question

Accepted Answer

Donanemab Shows Reduced Efficacy in Alzheimer's Patients with Higher Tau Protein Levels

For individuals with elevated levels of tau protein, Eli Lilly's experimental drug donanemab demonstrated a less pronounced effect in slowing the progression of Alzheimer's disease. Specifically, the drug was shown to slow disease progression by approximately 17 per cent in patients with high tau levels. This contrasts with the more significant benefit observed in patients with low-to-intermediate tau levels, where the drug slowed progression by 35 per cent.
Reduced Benefit Observed in High Tau Group

The full analysis of the trial data revealed that the efficacy of donanemab was diminished in patients exhibiting higher concentrations of tau protein. While the drug offered a 17 per cent slowing of disease progression in this subgroup, this benefit was considerably less robust compared to those with lower or intermediate tau levels, who experienced a 35 per cent slowing. These findings highlight a correlation between tau protein levels and the drug's effectiveness.
Clinical Significance of Tau Protein in Alzheimer's

Tau protein is intrinsically linked to the progression of Alzheimer's disease. Elevated tau levels are often indicative of more advanced neurodegeneration, which can impact how a patient responds to treatments aimed at clearing amyloid plaques, the primary target of donanemab. The differing efficacy based on tau levels suggests that the underlying pathological processes in patients with higher tau may be less responsive to this particular therapeutic mechanism.
Broader Context of Alzheimer's Treatment Goals

Current treatment approaches for Alzheimer's disease, including drugs like donanemab and the recently approved Leqembi, aim to modify the disease's course by targeting underlying pathologies, such as amyloid beta plaque accumulation. The clinical goal is generally to slow cognitive decline and preserve function for as long as possible. While donanemab showed a 60 per cent slowing of progression in the earliest stages of the disease overall, the reduced benefit in patients with high tau levels indicates that these therapies may not offer the same degree of impact across all patient profiles within the Alzheimer's spectrum.

Reading history

Hide →

This history is cleared when the page is closed.

How effective is donanemab for patients with higher tau protein levels?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends